These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading "Risk Factors" included in BioAge's prospectus dated September 25, 2024 filed with the U.S.
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity
Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029
The story "BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates" has 1377 words across 23 sentences, which will take approximately 6 - 12 minutes for the average person to read.
Which news outlet covered this story?
The story "BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates" was covered 1 days ago by Benzinga, a news publisher based in United States.
How trustworthy is 'Benzinga' news outlet?
Benzinga is a fully independent (privately-owned) news outlet established in 2010 that covers mostly investing and business news.
The outlet is headquartered in United States and publishes an average of 1 news stories per day.
It's most recent story was published 1 days ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
